1. Scrip
  2. >>Therapy Areas

AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV

 
• By Jessica Merrill

FDA approval of the glecaprevir/pibrentasvir combination could help AbbVie fill a gap resulting from declining sales of Viekira Pak, while challenging Gilead's monopoly in some segments of the market.

AbbVie Inc.'s next-generation combination therapy for hepatitis C, Mavyret (glecaprevir/pibrentasvir), will be the first eight-week regimen to treat all non-cirrhotic genotypes of the virus, narrowing the treatment window from what previously was 12 weeks. Marvyret could help AbbVie fill a gap left by declining sales of its first HCV combination Viekira Pak and challenge rival Gilead Sciences Inc.'s near-monopoly, particularly in genotypes 2 and 3 of the virus.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.